Plain-English translation of NCT04510129 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying tumor tissue samples taken before patients start immunotherapy treatment with PD-1/PD-L1 inhibitors to develop a test that can predict which patients will respond best to the medication. By analyzing these samples alongside treatment outcomes, scientists hope to understand what features in a tumor tell us whether this treatment will work. This could one day help doctors choose the best cancer treatment for each patient.
Immunotherapy works very well for some cancer patients but not others, and doctors currently have no reliable way to predict who will benefit before starting treatment. This study aims to develop a test that can identify which patients are most likely to respond to this medication, so doctors can make smarter treatment decisions from the start.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would give permission for researchers to use your existing tumor biopsy sample (which was already taken as part of your regular cancer care) along with your medical imaging scans and health information for this study. No additional biopsies or procedures are required—the researchers work with samples and records you already have. You would also consent for your tissue to be used in future research to develop and test the new diagnostic tool.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Sponsor
Cofactor Genomics, Inc.
Collaborators
Curebase Inc.
Enrollment target
~1,650 participants
Started
February 2020
Primary completion
February 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Clinical Trial Coordinator
Cofactor Genomics
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.